Episurf has completed the first closing of the acquired real estate assets, convenes an extraordinary general meeting and announces a board change

Episurf Medical AB (publ) (NASDAQ: EPIS B) ("Episurf" or the "Company") announced on 30 December 2025, that the Company has entered into an agreement to acquire real estate assets from Goldcup 38657 AB (under name change to Frusipe Intressenter Holding AB) (the "Seller"). Episurf has today acquired all shares in Goldcup 38658 AB (under name change to Frusipe Intressenter Target 1 AB) (the "Target Company") which, currently through subsidiaries, holds and manages property portfolios consisting of a total of 4 Swedish properties, with a total agreed underlying property value of approximately SEK 273 million (the "Completed Property Portfolio") as well as property-related debt securities in the form of senior unsecured green notes issued by Ilija Batljan Invest AB, with a total nominal amount of SEK 700 million. Episurf also announces that board member Christian Krüeger will leave his position as a board member of Episurf in connection with the extraordinary general meeting that will consider approval of the acquisition. Jens Andersson, former CFO of Castellum, is proposed as a new board member. The notice convening the meeting will be published separately today. In addition to approval of the acquisition and board changes, the meeting will also resolve on amendments to the articles of association and authorization for the board to resolve on issuance of B-shares, convertibles and warrants as payment for part of the acquisition.

The Completed Property Portfolio consists of the properties TÄBY MIKROMETERN 16, LINKÖPING MAGNETEN 1, NORRTÄLJE HALLSTA 38:1 and NORRTÄLJE PELIKANEN 8. As described in more detail in the press release dated 30 December 2025, closing of the second part of the property portfolio, with an underlying property value of approximately SEK 470 million, is conditional and is intended to be completed later.

Jens Andersson has extensive experience from banking, real estate and capital markets and was most recently CFO at Castellum. He has previously been financial director with responsibility for the American market at Corem Property Group AB/Klövern AB and CEO of several subsidiaries. He has also worked as project manager at Catella Corporate Finance, been co-founder and CFO at Vanir AM and before that First Vice President at Aareal Bank AG.

For more information, please contact:

Pål Ryfors, Acting CFO, Episurf Medical

Phone: +46 709 623 669

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical works to offer people with painful joint injuries a more active and healthier life by making minimally invasive and tailored treatment options available. Episurf Medical's individualized implants Episealer® and surgical instruments Epiguide® are used for the treatment of local cartilage damage in joints. With Episurf Medical's μiFidelity® system, the implants are cost-effectively adapted to each person's unique injury for optimal fit and minimal intervention. Episurf Medical is headquartered in Stockholm, Sweden. The share (EPIS B) is listed on Nasdaq Stockholm. More information can be found on the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, 17:40 CET on January 8, 2026.